• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/18

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

18 Cards in this Set

  • Front
  • Back
oral contraceptive use influence on ovarian cancer
OCP use decreases risk of ovarian cancer
biggest factor in decreasing risk of ovarian cancer
decreased number of ovulatory cycles (OC's, mult pregnancies, tubal ligation, etc)
BRCA-1 and BRCA-2 mutation influence on ovarian ca
survival better in pts w/ BRCA-1 or -2 mutations than sporadic cancer
ovarian screening
no effective screening test
recommendation for women at low/standard risk ovarian
annual physical and pelvic exam
recommendation for women at high risk ovarian
pelvic exam, transvaginal ultrasound and CA-125 every 6-12 months starting at age 25-35
normal range for CA-125
0-35 U/mL
treatment: early stage ovarian w/ favorable features
surgery
treatment: early stage ovarian w/ unfavorable features
surgery followed by
paclitaxel + carbo q3w x 6 cyc
treatment: ovarian stage II- 2 alternatives
1) IP+IV chemo
2) docetaxel + carbo q3w x 6
treatment: ovarian stage III & IV
surgery + chemo of taxane & platinum x 6 cycles. IP chemo is preferred route for select pts
carbo vs cisplatin in ovarian
carbo preferred due to less toxicity and equal efficacy
cisplatin + paclitaxel q3w same day recommendation in ovarian
not recommended for routine use due to increased neurotoxicity
docetaxel vs paclitaxel in ovarian
docetaxel is less neurotoxic and equally effective
treatment options for recurrent ovarian cancer
1) paclitaxel + carbo
2) gemcitabine + carbo
3) carbo single agent
4) paclitaxel single agent
salvage agents for ovarian cancer
Doxil, topotecan, vinorelbine
CA-125 laboratory variation
significant, should draw at same lab for consistency
Ovarian cancer symptoms: (4)
bloating, pelvic/abdominal pain, difficulty eating or feeling full, urinary symptoms